Antenatal care attendees positive for syphilis who received treatment in Burkina Faso
Burkina Faso: Antenatal care attendees positive for syphilis who received treatment was 86.5% in 2024. ▼ Falling
Antenatal care attendees positive for syphilis who received treatment in Burkina Faso, 2010–2024
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for antenatal care attendees positive for syphilis who received treatment in Burkina Faso is 86.5%, measured in 2024. That is the lowest value across all 9 years on record.
That represents a change of down 13.5% on the previous year and down 13.5% over ten years.
Over the whole period, antenatal care attendees positive for syphilis who received treatment in Burkina Faso peaked at 100.0% in 2010 and was at its lowest, 86.5%, in 2024.
That places Burkina Faso 55th out of 79 countries with data for 2024, putting it in the middle of the range.
Antenatal care attendees positive for syphilis who received treatment in Burkina Faso, year by year
| Year | Value | Change |
|---|---|---|
| 2010 | 100.0% | — |
| 2011 | 100.0% | +0.0% |
| 2012 | 100.0% | +0.0% |
| 2014 | 100.0% | +0.0% |
| 2016 | 100.0% | +0.0% |
| 2017 | 100.0% | +0.0% |
| 2020 | 100.0% | +0.0% |
| 2021 | 100.0% | +0.0% |
| 2024 | 86.5% | -13.5% |
Burkina Faso compared with similar countries
- Burkina Faso's 86.5% is below the median for low income countries, which is 91.7%, 94% of the median. (12 countries reporting)
- Burkina Faso's 86.5% is below the median for Sub-Saharan Africa, which is 92.8%, 93% of the median. (28 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 100.0% | 100.0% | 100.0% | 6 |
| 2020s | 95.5% | 86.5% | 100.0% | 3 |
Countries ranked near Burkina Faso
More health data for Burkina Faso
- Un projection of annual infant deaths, annual growth rate -1.67 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.8925 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,142 deaths per 1,000 people (2090)
- Number of infants who die before age 1 13,085 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 4 (2025)
- Population ages 00-04, female, annual growth rate 0.8681 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0693 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.7133 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0.0001 units per US$ of GDP (2025)
Frequently asked questions
- What is antenatal care attendees positive for syphilis who received treatment in Burkina Faso?
- Antenatal care attendees positive for syphilis who received treatment in Burkina Faso was 86.5% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest antenatal care attendees positive for syphilis who received treatment recorded in Burkina Faso?
- The highest recorded value was 100.0% in 2010.
- What is the lowest antenatal care attendees positive for syphilis who received treatment recorded in Burkina Faso?
- The lowest recorded value was 86.5% in 2024.
- How does Burkina Faso rank for antenatal care attendees positive for syphilis who received treatment?
- Burkina Faso ranks 55th out of 79 countries with data for 2024.
- Is antenatal care attendees positive for syphilis who received treatment rising or falling in Burkina Faso?
- Over the last ten years it is down 13.5%. The long-run trend across the full record is falling.
- Where does this Burkina Faso data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Antenatal care attendees positive for syphilis who received treatment (%), reported. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 9 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).